Efficacy of Bee Venom as an Anti-viral Therapy for HCV Genotype 4

Abd Elrazek M Ali Abd Elrazek

Authors

Abd Elrazek M Ali Abd Elrazek

Keywords:

bee venom, HCV, traditional, therapy

Abstract

Use of traditional medicine is encouraged in many economically diverse countries when conventional medic- ations fail. HCV prevalence is highest in Egypt at >10% of the general population, and China has the most people with HCV (29.8 million); approximately 52% of patients infected with HCV genotype 4 will develop chronic HCV. The use of interferon, currently the only approved therapy, is frustrating in many situations. Use of camel milk or drinking copious amounts of urine, moxibustion by fire, acupuncture and cupping, especially in the Saharan and Arabian areas, is currently popular in Egypt. Some traditional Egyptian medicine is related to Arabian, ancient Egyptian, or other religious beliefs. Most patients using traditional therapies show improvement over time in both clinical symptoms and laboratory results. Some showed SVR using Bee venom therapy.

Downloads

How to Cite

Efficacy of Bee Venom as an Anti-viral Therapy for HCV Genotype 4. (2014). Global Journal of Medical Research, 14(14), 15-18. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

Author Biography

Abd Elrazek M Ali Abd Elrazek

Lecturer Hepatologist,Researcher - Aswan School of Medicine, Aswan University-Egypt. awarded PHD,MD in Medicine of Liver Transplantation from Kobe International medical frontier-Kobe-Japan, in 2012. awarded PHD. Tropical Medicine-Al Azhar university -Egypt, in 2014. Fellowship in Transplant Hepatology; University of California Los Angeles; UCLA; CA,USA; 2105 Researcher (medical data mining), have plenty of publications related. Visiting Assistant Project Scientist; Liver Transplant and Surgery; UCLA,USA; 2015

References

Mohd Hanafiah, K. Groeger, J. Flaxman, A. Wiersma, S. (2013) Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. 57, 1333.

Hajarizadeh B, Grebely J, Dore GJ (2013) Epidemiology and natural history of HCV infection Nat Rev Gastroenterol Hepatol. 10(9), 553-562.

Kenny-Walsh E. (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. 340, 1228.

(1999) Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. 341(12), 866. https://doi.org/10.1056/nejm199909163411202

(1995) Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. 123(5), 330. https://doi.org/10.7326/0003-4819-123-5-199509010-00002

T. Heintges, J. Wands (1997) Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. 26(3), 521-526. https://doi.org/10.1002/hep.510260338

(2010) A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. 139(5), 1593. https://doi.org/10.1053/j.gastro.2010.07.009

(2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. 54(4), 1433. https://doi.org/10.1002/hep.24641

(2012) UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. 35(6), 647. https://doi.org/10.1111/j.1365-2036.2012.04992.x

Wilt TJ, Ishani A, Stark G (1998) Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. 280(18), 1604. https://doi.org/10.1001/jama.280.18.1604

Papastergiou V, Dimitroulopoulos D, Skorda L, Lisgos P, Ketikoglou I, Kostas N, Karatapanis S (2012) Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol. 84(8), 1217-1223.

Abdel-Moneim AS, Bamaga MS, Shehab GM, Abu- AA, Farahat FM (2012) HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rate. 7(1), e29781.

Shakil AO, Conry-Cantilena C, Alter HJ (1995) Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. 123(5), 330. https://doi.org/10.7326/0003-4819-123-5-199509010-00002

J. Lee, S.Y.Kim, T.W.Kim, S.H.Lee (2004) Anti- Inflammatory effect of bee venom on type II collagen-Induced arthritis. 32, 361-367.

Soo-Yung Kim (2010) Bee Venom Inhibits Hepatic Fibrosis Through Suppression of Pro-Fibrogenic Cytokine Expression. 38(05), 921-935. https://doi.org/10.1142/s0192415x10008354